Multidrug-resistant tuberculosis: Standardized or individualized treatment? the question has already been answered

Expert Review of Respiratory Medicine

Volumn 4, Issue 2, 2010, Pages 143-146

  Laniado Laborn, Rafael ^a  

^a Baja California University   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

DISEASE SURVEILLANCE; DRUG RESPONSE; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PERSONALIZED MEDICINE; PREVALENCE; RESOURCE ALLOCATION; SHORT COURSE THERAPY; SOCIOECONOMICS; TREATMENT DURATION; TUBERCULOSIS CONTROL;

EID: 77951444242     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.6     Document Type: Editorial

References (23)

1. Han LL, Sloutsky A, Canales R et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int. J. Tuberc. Lung Dis. 9, 818-821 (2005).
2. Nathanson E, Lambregts-van Weezenbeek C, Rich ML et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg. Infect. Dis. 12, 1389-1397 (2006).
3. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.411. WHO, Geneva, Switzerland (2009).
4. Pablos-Mendez A, Raviglione MC, Laszlo A et al. for the World Health Organization - International Union Against Tuberculosis and Lung Disease Working Group on Drug Resistance Surveillance. Global surveillance for antituberculosis-drug resistance, 1994-1997. N. Engl. J. Med. 339, 139 (1998).
5. Chana ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr. Opin. Infect. Dis. 21, 587-595 (2008).
6. Lan NTN, Lademarco MF, Binkin NJ, Tung LB, Quy HT, CJ̌NV. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Int. J. Tuberc. Lung Dis. 5, 575-578 (2001).
7. World Health Organization. Treatment of tuberculosis: guidelines for national programmes (3rd edition). WHO/CDS/ TB/2003.313. WHO, Geneva, Switzerland (2003).
8. Mak A, Thomas A, del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am. J. Respir. Crit. Care Med. 178, 306-312 (2009).
9. Espinal MA, Kim SJ, Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcome in 6 countries. JAMA 283, 2537-2545 (2000).
10. Leimane V, Riekstina V, Holtz TH et al. Clinical outcome of individualised treatment of multidrugresistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365, 318-326 (2005).
11. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC. Frequency of recurrence among MDR-TB cases 'successfully' treated with standardised short-course chemotherapy. Int. J. Tuberc. Lung Dis. 6, 858-864 (2002).
12. Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int. J. Tuberc. Lung Dis. 12, 869-877 (2008).
13. Espinal MA. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int. J. Tuberc. Lung Dis. 7, 607-608 (2003).
14. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur. Respir. J. 25, 928-936 (2005).
15. World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis. WHO/CDS/ TB/2000.279. WHO, Geneva, Switzerland (2000).
16. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. WHO/HTM/TB/2008.402. WHO, Geneva, Switzerland (2008).
17. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians (Second Edition). Francis J Curry National Tuberculosis Center and California Department of Public Health, CA, USA, 33-56 (2008).
18. Suárez PG, Floyd K, Portocarrero J et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359, 1980-1989 (2002).
19. Mitnick C, Bayona J, Palacios E et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 348, 119-128 (2003).
20. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int. J. Tuberc. Lung Dis. 8, 361-368 (2004).
21. Yong Kim J, Shakow A, Mate K, Vanderwarker C, Gupta R, Farmer P. Limited good and limited vision: multidrug-resistant tuberculosis and global health policy. Social Sci. Med. 61, 847-859 (2005).
22. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 4(11), e292 (2005).
23. Iseman M. Tailoring a time-bomb. Am. Rev. Respir. Dis. 132, 735 (1985).